Australia markets open in 5 hours 25 minutes

Theranexus Société Anonyme (ALTHX.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
8.26-0.40 (-4.62%)
At close: 5:38PM CEST

Theranexus Société Anonyme

60 avenue Rockefeller
Pépinière Laennec
Lyon 69008

Full-time employees18

Key executives

NameTitlePayExercisedYear born
Mr. Franck MouthonChairman & CEO280.98kN/AN/A
Mr. Mathieu CharvériatChief Scientific Officer, Deputy CEO & Director240.48kN/AN/A
Mr. Thierry LambertCFO and Admin. & Financial directorN/AN/A1954
Mr. Julien VeysChief Bus. Devel. OfficerN/AN/AN/A
Mr. Werner ReinChief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.

Corporate governance

Theranexus Société Anonyme’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.